Following publication of the results of the PROLONG trial, The American College of Obstetricians and Gynecologists (ACOG) and the Society of Maternal Fetal Medicine Specialists (SMFM) have each released statements regarding the use of progesterone for prevention of preterm birth.

ACOG STATEMENT: https://www.acog.org/About-ACOG/News-Room/Statements/2019/ACOG-Statement-on-17p-Hydroxyprogesterone-Caproate

SMFM STATEMENT: https://els-jbs-prod-cdn.literatumonline.com/pb/assets/raw/Health%20Advance/journals/ymob/SMFM_Statement_PROLONG-1572023839767.pdf

An advisory committee of the FDA voted on October 29 to recommend that the FDA pursue withdrawal of approval for hydroxyprogesterone caproate injection for the prevention of preterm birth. The vote was nearly split at 9-7.